
How Participation in a Securities Fraud Class Action Works
Guide to securities fraud class actions and how investors participate.

BlackRock TCP Capital Corp. (TCPC) Investors Sue Over Alleged NAV Inflation and Portfolio Valuation Failures
Learn about securities lawsuits tied to your portfolio and recover money!
BlackRock TCP Capital Corp., a publicly traded business development company, is facing a federal securities class action that centers on one number investors treat as sacred: net asset value. According to the complaint, shareholders allege that TCPC overstated the value of its investment portfolio by failing to timely and appropriately mark troubled assets, masking unrealized losses until disclosures on February 27, 2025 and January 23, 2026 triggered sharp stock declines.
The lawsuit, filed in the U.S. District Court for the Central District of California, covers investors who purchased TCPC securities between November 6, 2024, and January 23, 2026. It names the company and senior executives, including its former and current chief executive officers and its chief financial officer, accusing them of violating federal securities laws by presenting an inaccurately healthy picture of the company’s portfolio and financial condition.
“Most TCPC shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
BlackRock TCP Capital Corp. operates as a business development company, or BDC. Its business model is straightforward in theory but complex in execution: raise capital from public investors and deploy it into loans and structured investments made primarily to middle-market companies. Returns are generated through interest income, origination fees, and, to a lesser extent, equity appreciation.
Because most BDC investments are not publicly traded, valuation becomes both essential and subjective. Investors rely heavily on quarterly reported net asset value per share to assess portfolio health, regulatory compliance, and whether shares are trading at a premium or discount to underlying assets. As alleged in the complaint, TCPC repeatedly emphasized that its investments were valued at least quarterly and largely based on independent pricing sources, with only a small portion valued directly by its valuation designee, an affiliate of BlackRock.
Throughout the class period, TCPC issued press releases and filed periodic reports describing its portfolio as stabilizing, improving, or well diversified. Management highlighted declining non-accruals, progress in resolving challenged credits, and confidence that restructuring efforts were producing results.
In these disclosures, the Company stated that its investments were recorded at fair value in accordance with GAAP and described its valuation methodology for determining those values. Quarterly and annual filings reiterated that assets were valued in accordance with GAAP and that valuation methodologies were designed to provide a reasonable estimate of what those investments would fetch in an orderly transaction.
The complaint tells a different story. Investors allege that these reassurances masked deeper valuation problems: investments were not being timely or appropriately marked, restructuring efforts were not actually improving credit quality, unrealized losses were understated, and net asset value was therefore inflated. In January 2026, the Company disclosed a preliminary estimate of its December 31, 2025 NAV per share of approximately $7.05 to $7.09, which plaintiffs allege reflected previously undisclosed portfolio deterioration.
The alleged misconduct begins in November 2024, when TCPC reported third-quarter results and described signs of improvement in its portfolio. In early 2025, that narrative began to fracture. A February press release disclosed a year-over-year decline in net asset value of more than 22 percent and a sharp increase in non-accrual investments, accompanied by nearly a 10 percent one-day stock drop.
While management continued to emphasize progress and stabilization, subsequent quarterly filings reported NAV per share of $9.18 as of March 31, 2025 and $8.71 as of June 30, 2025. The final alleged corrective disclosure came in January 2026, when TCPC revealed preliminary estimates showing net asset value per share had fallen to roughly $7.05–$7.09, a steep decline from prior reported levels. The market reaction was immediate, with shares falling nearly 13 percent in one trading session.
According to the complaint, these disclosures caused significant losses to investors who purchased TCPC shares at prices allegedly inflated by misleading statements. The Complaint alleges that on February 27, 2025, TCPC’s stock declined approximately 9.64% following the Company’s disclosure of year-over-year NAV decline and increased non-accruals, and that on January 26, 2026, the stock declined approximately 12.97% following disclosure of its preliminary December 31, 2025 NAV estimate.
Plaintiffs allege that the stock declines were caused by the disclosure of previously concealed adverse information regarding the Company’s portfolio valuation and financial condition. Plaintiffs allege that once the Company disclosed updated NAV information and issuer-specific developments in January 2026, the stock price declined, resulting in investor losses.
The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Defendants include BlackRock TCP Capital Corp. and senior executives who signed or were responsible for the challenged disclosures. Plaintiffs allege scienter, asserting that the defendants knew or recklessly disregarded that portfolio valuations and restructuring claims were misleading. The complaint also invokes the fraud-on-the-market doctrine, arguing that TCPC shares traded in an efficient market and that investors relied on the integrity of public disclosures when purchasing shares. The case is in its early stages, with no merits determinations yet made by the court.
Market reaction to BlackRock TCP Capital Corp.’s disclosures underscores how closely Business Development Company (BDC) investors track changes in net asset value and credit quality. Because BDC shares frequently trade relative to reported NAV, unexpected markdowns or increases in non-accrual investments can quickly prompt investors to reassess portfolio stability. When TCPC disclosed a significant year-over-year decline in NAV and rising non-accrual exposure in early 2025, the stock sold off sharply, reflecting a rapid recalibration of perceived portfolio risk. A later preliminary update in January 2026 estimating NAV at roughly $7.05 to $7.09 per share intensified that reassessment and focused attention on issuer-specific developments within several portfolio companies.
Episodes like these often trigger broader scrutiny from investors evaluating the quality of underlying loans and the reliability of prior valuation marks. Within the BDC sector, sudden changes in NAV frequently prompt investors to revisit assumptions about portfolio health, dividend sustainability, and the stability of underlying credit exposures.
Wall Street analysts have historically viewed TCPC through the lens of its middle-market exposure, but recent issuer-specific developments have intensified scrutiny of the company’s underlying portfolio. Following the January 2026 update, several financial outlets pointed out that the 19% NAV decline was far steeper than the broader BDC industry average, suggesting deep-seated issues within the underlying portfolio companies rather than simple macroeconomic headwinds.
Financial analysts at Seeking Alpha have focused on TCPC’s non-accrual exposure and portfolio credit quality, particularly after the company disclosed additional markdowns and a sharp drop in reported NAV. Subsequent reporting indicated that six portfolio companies accounted for roughly two-thirds of the decline, reinforcing concerns about concentrated credit stress. Further analysis from Yahoo Finance highlighted that the stock’s move to a significant discount against its reported NAV was a direct result of the market losing faith in the company’s internal valuation marks.
Because BDC valuations require judgment in estimating the fair value of illiquid investments, abrupt markdowns often lead analysts and investors to reassess asset quality, valuation assumptions, and portfolio risk. Against that backdrop, the complaint’s theory tracks a broader market question: whether earlier disclosures adequately reflected those valuation pressures before the later markdowns were announced.
TCPC’s SEC filings repeatedly acknowledged that valuing illiquid investments involves judgment and uncertainty. Risk disclosures warned that net asset value could be overstated and that economic downturns or borrower distress could impair portfolio companies.
Plaintiffs argue that these warnings were insufficient because they framed valuation risks as hypothetical, even as the alleged problems were already materializing. According to the complaint, disclosures about potential overstatement did not cure the failure to reveal that valuation methods were already producing inflated results.
How to Join the BlackRock TCP Capital Corp. (TCPC) Class Action
At its core, the TCPC lawsuit is about trust in reported numbers. Net asset value is not just an accounting figure for BDC investors; it is the lens through which portfolio health is judged. The complaint alleges that when that lens is distorted by delayed recognition of portfolio deterioration, the consequences can be swift once new information reaches the market.
For investors, the case underscores the importance of scrutinizing valuation practices and understanding how quickly market reactions can follow disclosures that alter assumptions about portfolio value. The case now turns on whether those earlier disclosures accurately reflected the condition of the company’s investments or whether key information about portfolio valuations should have been revealed sooner.
As the litigation moves forward, investors and market observers will be watching closely to see how the allegations surrounding NAV reporting, portfolio credit quality, and disclosure practices ultimately play out in court.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Guide to securities fraud class actions and how investors participate.

Varonis Systems faces a securities class action alleging misleading statements about growth and business performance.

Inovio Pharmaceuticals (INO) Securities Class Action: FDA Setback, Manufacturing Deficiencies, and the Cost of Delayed Truth